Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications
Introduction: The existing treatment options for osteoarthritis (OA) fall short of addressing the significant challenges this disease imposes on patients in today's society. It markedly diminishes the quality of life of those affected and is one of the leading causes of disability. While c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2024-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/48093 |
| _version_ | 1827353578629496832 |
|---|---|
| author | Katarzyna Sokołowska Dawid Bereza Maria Kulak Igor Moreau Paulina Polańska Miriam Lang Barbara Woch |
| author_facet | Katarzyna Sokołowska Dawid Bereza Maria Kulak Igor Moreau Paulina Polańska Miriam Lang Barbara Woch |
| author_sort | Katarzyna Sokołowska |
| collection | DOAJ |
| description |
Introduction:
The existing treatment options for osteoarthritis (OA) fall short of addressing the significant challenges this disease imposes on patients in today's society. It markedly diminishes the quality of life of those affected and is one of the leading causes of disability. While conventional pharmacological interventions such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids effectively address pain, they are not intended to halt disease progression and are associated with potential health risks. Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) and innovative medications, rooted in our expanding understanding of OA pathogenesis, offer promising prospects for discovering improved treatment modalities.
State of knowledge:
The evolving understanding of OA's etiology highlights the necessity for tailored treatments that consider distinct disease phenotypes. This review critically examines SYSADOA, specifically focusing on chondroitin sulfate, glucosamine, and avocado-soybean unsaponifiables, as agents designed to address the underlying pathology of OA. Chondroitin sulfate demonstrates potential disease-modifying effects, however with conflicting study results that underscore the extent of its efficacy. Glucosamine exhibits varying disease-modifying effects, with short-term trials demonstrating more promising outcomes in pain reduction. Avocado-soybean unsaponifiables show promise in alleviating knee OA pain, yet their impact on hip OA symptoms remains inconclusive. The review extends its scope to novel drugs with potential disease-modifying effects, exploring proteinase inhibitors, fibroblast growth factors, Wnt-signaling pathway inhibitors, senolytic agents, anti-nerve growth factor agents, and transforming growth factor-β.
Conclusions:
Although preliminary studies indicate potential for certain novel agents, challenges and adverse effects necessitate further investigation through rigorous, high-quality research.
|
| first_indexed | 2024-03-08T03:28:30Z |
| format | Article |
| id | doaj.art-80e2a58240ae4855ac0ca2650fc76a1d |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-03-08T03:28:30Z |
| publishDate | 2024-02-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-80e2a58240ae4855ac0ca2650fc76a1d2024-02-11T11:52:43ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062024-02-015810.12775/JEHS.2024.58.008Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative MedicationsKatarzyna Sokołowska0Dawid Bereza1Maria Kulak2Igor Moreau3Paulina Polańska4Miriam Lang5Barbara Woch6Dr Alfred Sokolowski Specialist Hospital in Walbrzych, A. Sokołowskiego 4, 58-309 Walbrzych, PolandDr Alfred Sokolowski Specialist Hospital in Walbrzych, A. Sokołowskiego 4, 58-309 Walbrzych, PolandPomeranian Hospitals LLC, Polish Red Cross Maritime Hospital, Powstania Styczniowego 1, 81-519 Gdynia, PolandDivision of Pathophysiology, Department of Physiology and Pathophysiology, Wroclaw Medical University, Tytusa Chałubińskiego 10, 50-368 Wroclaw, PolandFaculty of Medicine, Wroclaw Medical University, Wybrzeże L. Pasteura 1, 50-367 Wroclaw, PolandLower Silesian Oncology Centre, Plac Ludwika Hirszfelda 12, 53-413 Wrocław, PolandPoviat Hospital Complex; Poviat Hospital in Oleśnica, Armii Krajowej 1, 56-400 Oleśnica Introduction: The existing treatment options for osteoarthritis (OA) fall short of addressing the significant challenges this disease imposes on patients in today's society. It markedly diminishes the quality of life of those affected and is one of the leading causes of disability. While conventional pharmacological interventions such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids effectively address pain, they are not intended to halt disease progression and are associated with potential health risks. Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) and innovative medications, rooted in our expanding understanding of OA pathogenesis, offer promising prospects for discovering improved treatment modalities. State of knowledge: The evolving understanding of OA's etiology highlights the necessity for tailored treatments that consider distinct disease phenotypes. This review critically examines SYSADOA, specifically focusing on chondroitin sulfate, glucosamine, and avocado-soybean unsaponifiables, as agents designed to address the underlying pathology of OA. Chondroitin sulfate demonstrates potential disease-modifying effects, however with conflicting study results that underscore the extent of its efficacy. Glucosamine exhibits varying disease-modifying effects, with short-term trials demonstrating more promising outcomes in pain reduction. Avocado-soybean unsaponifiables show promise in alleviating knee OA pain, yet their impact on hip OA symptoms remains inconclusive. The review extends its scope to novel drugs with potential disease-modifying effects, exploring proteinase inhibitors, fibroblast growth factors, Wnt-signaling pathway inhibitors, senolytic agents, anti-nerve growth factor agents, and transforming growth factor-β. Conclusions: Although preliminary studies indicate potential for certain novel agents, challenges and adverse effects necessitate further investigation through rigorous, high-quality research. https://apcz.umk.pl/JEHS/article/view/48093SenotherapeuticsOsteoarthritisAnti-Inflammatory Agents, Non-SteroidalGlucosamineChondroitin SulfatesMatrix Metalloproteinase Inhibitors |
| spellingShingle | Katarzyna Sokołowska Dawid Bereza Maria Kulak Igor Moreau Paulina Polańska Miriam Lang Barbara Woch Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications Journal of Education, Health and Sport Senotherapeutics Osteoarthritis Anti-Inflammatory Agents, Non-Steroidal Glucosamine Chondroitin Sulfates Matrix Metalloproteinase Inhibitors |
| title | Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications |
| title_full | Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications |
| title_fullStr | Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications |
| title_full_unstemmed | Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications |
| title_short | Exploring Future Horizons in Osteoarthritis Relief: Unveiling the Potential of Slow-Acting Drugs and Innovative Medications |
| title_sort | exploring future horizons in osteoarthritis relief unveiling the potential of slow acting drugs and innovative medications |
| topic | Senotherapeutics Osteoarthritis Anti-Inflammatory Agents, Non-Steroidal Glucosamine Chondroitin Sulfates Matrix Metalloproteinase Inhibitors |
| url | https://apcz.umk.pl/JEHS/article/view/48093 |
| work_keys_str_mv | AT katarzynasokołowska exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications AT dawidbereza exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications AT mariakulak exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications AT igormoreau exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications AT paulinapolanska exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications AT miriamlang exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications AT barbarawoch exploringfuturehorizonsinosteoarthritisreliefunveilingthepotentialofslowactingdrugsandinnovativemedications |